- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT05063552
Testowanie stosowania leków badawczych Atezolizumab i/lub Bevacizumab ze standardową chemioterapią lub bez niej w leczeniu drugiego rzutu zaawansowanego raka głowy i szyi
Badanie fazy II/III chemioterapii + cetuksymab vs. chemioterapia + bewacyzumab vs. atezolizumab + bewacyzumab po progresji hamowania immunologicznego punktu kontrolnego w nawracających/przerzutowych rakach głowy i szyi
This phase II/III compares the standard therapy (chemotherapy plus cetuximab) versus adding bevacizumab to standard chemotherapy, versus combination of just bevacizumab and atezolizumab in treating patients with head and neck cancer that has spread to other places in the body (metastatic or advanced stage) or has come back after prior treatment (recurrent). Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Cetuximab is in a class of medications called monoclonal antibodies. It binds to a protein called EGFR, which is found on some types of cancer cells. This may help keep cancer cells from growing. Cisplatin and carboplatin are in a class of chemotherapy medications known as platinum-containing compounds. They work by killing, stopping, or slowing the growth of cancer cells. Docetaxel is in a class of chemotherapy medications called taxanes. It stops cancer cells from growing and dividing and may kill them. The addition of bevacizumab to standard chemotherapy or combination therapy with bevacizumab and atezolizumab may be better than standard chemotherapy plus cetuximab in treating patients with recurrent/metastatic head and neck cancers.
Przegląd badań
Status
Warunki
- Nawracający rak płaskonabłonkowy głowy i szyi
- Nawracający rak płaskonabłonkowy gardła dolnego
- Nawracający rak płaskonabłonkowy krtani
- Rak płaskonabłonkowy głowy i szyi z przerzutami
- Stopień kliniczny IV zależny od HPV (p16-dodatni) rak jamy ustnej i gardła AJCC v8
- Rak gardła dolnego stopnia IV AJCC v8
- Rak krtani w stadium IV AJCC v8
- IV stadium raka wargi i jamy ustnej AJCC v8
- Stopień IV Rak jamy ustnej i gardła (p16-ujemny) AJCC v8
- Przerzutowy rak płaskonabłonkowy dolnego gardła
- Przerzutowy rak płaskonabłonkowy krtani
- Przerzutowy rak wargi i jamy ustnej
- Przerzutowy rak płaskonabłonkowy jamy nosowej
- Rak płaskonabłonkowy jamy nosowo-gardłowej z przerzutami
- Rak płaskonabłonkowy gardła z przerzutami
- Rak płaskonabłonkowy zatok przynosowych z przerzutami
- Nawracający rak płaskonabłonkowy wargi i jamy ustnej
- Nawracający rak płaskonabłonkowy nosogardzieli
- Nawracający rak płaskonabłonkowy gardła
- Nawracający rak płaskonabłonkowy zatok przynosowych
- Rak nosowo-gardłowy stopnia IV AJCC v8
- Rak zatok przynosowych IV stadium AJCC v8
- STAPOWA IV Głowa i szyja rak płaskonabłonkowy AJCC V8
Interwencja / Leczenie
Szczegółowy opis
PRIMARY OBJECTIVES:
I. To evaluate progression-free survival (PFS) of patients treated with chemotherapy plus cetuximab, chemotherapy plus bevacizumab, and atezolizumab plus bevacizumab. (Phase II) II. To evaluate the overall survival (OS) of patients treated with chemotherapy plus cetuximab to the superior arm from the phase II portion of the protocol. (Phase III)
SECONDARY OBJECTIVES:
I. To evaluate the OS for the subset of patients with high PD-L1 expression, defined as combined positive score (CPS) >= 20% on all arms of treatment.
II. To evaluate the toxicity of each arm of treatment.
IMAGING OBJECTIVES:
I. To establish the correlation between fludeoxyglucose F-18 (18F-FDG) positron emission tomography (PET) and computed tomography (CT) neck imaging biomarkers (maximum standard uptake value [SUVmax], metabolic tumor volume [MTV], total lesion glycolysis [TLG], tumor volume) and expression of PD-L1 expression (Low versus high, defined as CPS < 20 versus CPS >= 20).
II. To determine if 18FDG-PET/CT and CT neck imaging biomarkers at baseline will predict treatment response at nine to twelve weeks post the initiation of treatment, PFS, and OS.
EXPLORATORY OBJECTIVE:
I. To establish the correlation between 18F-FDG PET and CT neck radiomics features and PD-L1 expressions (Low versus high - defined as CPS < 20 versus CPS >= 20).
OUTLINE: This is a randomized phase II trial followed by a randomized phase III trial.
PHASE II: Patients are randomized to 1 of 3 arms.
ARM A: Patients receive cetuximab intravenously (IV) over 60-120 minutes on days 1, 8, and 15 of each cycle, docetaxel IV over 1 hour on day 1 or days 1 and 8 of each cycle, and cisplatin IV or carboplatin IV on day 1 or days 1 and 8 of each cycle. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive cetuximab IV over 60-120 minutes on days 1, 8, and 15 or days 1 and 15 of each cycle of maintenance therapy. Cycles repeat every 21 days for 2 years in the absence of disease progression or unacceptable toxicity. Patients undergo a CT scan, a PET scan, and/or magnetic resonance imaging (MRI) throughout the trial. Patients may undergo echocardiography (ECHO) during screening.
ARM B: Patients receive bevacizumab IV over 30-90 minutes on day 1 of each cycle, docetaxel IV over 1 hour on day 1 or days 1 and 8 of each cycle, and cisplatin IV or carboplatin IV on day 1 or days 1 and 8 of each cycle. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive bevacizumab IV over 30-60 minutes on day 1 of each cycle of maintenance therapy. Cycles repeat every 21 days for 2 years in the absence of disease progression or unacceptable toxicity. Patients undergo a CT scan, a PET scan, and/or MRI throughout the trial. Patients may undergo ECHO during screening.
ARM C: Patients receive bevacizumab IV over 30-90 minutes on day 1 and atezolizumab IV over 30-60 minutes on day 1 of each cycle. Cycles repeat every 21 days for 2 years in the absence of disease progression or unacceptable toxicity. Patients undergo a CT scan, a PET scan, and/or MRI throughout the trial. Patients may undergo ECHO during screening.
PHASE III: Patients are randomized to 1 of 2 arms.
ARM A: Patients receive cetuximab IV over 60-120 minutes on days 1, 8, and 15 of each cycle, docetaxel IV over 1 hour on day 1 or days 1 and 8 of each cycle, and cisplatin IV or carboplatin IV on day 1 or days 1 and 8 of each cycle. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive cetuximab IV over 60-120 minutes on days 1, 8, and 15 or days 1 and 15 of each cycle of maintenance therapy. Cycles repeat every 21 days for 2 years in the absence of disease progression or unacceptable toxicity. Patients undergo a CT scan, a PET scan, and/or MRI throughout the trial. Patients may undergo ECHO during screening.
ARM B: Patients receive treatment as in Arm B or C above based on results of the Phase II trial.
Patients undergo blood sample collection throughout the study.
After completion of study treatment, patients are followed up at 30 days and then every 3 months if patient is < 2 years from randomization and every 6 months if patient is 2-5 years from randomization.
Typ studiów
Zapisy (Szacowany)
Faza
- Faza 2
- Faza 3
Kontakty i lokalizacje
Lokalizacje studiów
-
-
Arkansas
-
Little Rock, Arkansas, Stany Zjednoczone, 72205
- University of Arkansas for Medical Sciences
-
-
California
-
Dublin, California, Stany Zjednoczone, 94568
- Epic Care-Dublin
-
Emeryville, California, Stany Zjednoczone, 94608
- Epic Care Partners in Cancer Care
-
Irvine, California, Stany Zjednoczone, 92612
- UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care
-
Martinez, California, Stany Zjednoczone, 94553-3156
- Contra Costa Regional Medical Center
-
Orange, California, Stany Zjednoczone, 92868
- UC Irvine Health/Chao Family Comprehensive Cancer Center
-
Palo Alto, California, Stany Zjednoczone, 94304
- VA Palo Alto Health Care System
-
Palo Alto, California, Stany Zjednoczone, 94304
- Stanford Cancer Institute Palo Alto
-
-
Connecticut
-
Derby, Connecticut, Stany Zjednoczone, 06418
- Smilow Cancer Hospital-Derby Care Center
-
Fairfield, Connecticut, Stany Zjednoczone, 06824
- Smilow Cancer Hospital Care Center-Fairfield
-
Glastonbury, Connecticut, Stany Zjednoczone, 06033
- Smilow Cancer Hospital Care Center at Glastonbury
-
Greenwich, Connecticut, Stany Zjednoczone, 06830
- Smilow Cancer Hospital Care Center at Greenwich
-
Guilford, Connecticut, Stany Zjednoczone, 06437
- Smilow Cancer Hospital Care Center - Guilford
-
Hartford, Connecticut, Stany Zjednoczone, 06105
- Smilow Cancer Hospital Care Center at Saint Francis
-
New Haven, Connecticut, Stany Zjednoczone, 06520
- Yale University
-
North Haven, Connecticut, Stany Zjednoczone, 06473
- Yale-New Haven Hospital North Haven Medical Center
-
Orange, Connecticut, Stany Zjednoczone, 06477
- Smilow Cancer Hospital-Orange Care Center
-
Stamford, Connecticut, Stany Zjednoczone, 06902
- Smilow Cancer Hospital Care Center at Long Ridge
-
Torrington, Connecticut, Stany Zjednoczone, 06790
- Smilow Cancer Hospital-Torrington Care Center
-
Trumbull, Connecticut, Stany Zjednoczone, 06611
- Smilow Cancer Hospital Care Center-Trumbull
-
Waterbury, Connecticut, Stany Zjednoczone, 06708
- Smilow Cancer Hospital-Waterbury Care Center
-
Waterford, Connecticut, Stany Zjednoczone, 06385
- Smilow Cancer Hospital Care Center - Waterford
-
-
Delaware
-
Newark, Delaware, Stany Zjednoczone, 19713
- Helen F Graham Cancer Center
-
Newark, Delaware, Stany Zjednoczone, 19713
- Medical Oncology Hematology Consultants PA
-
-
District of Columbia
-
Washington D.C., District of Columbia, Stany Zjednoczone, 20010
- MedStar Washington Hospital Center
-
-
Florida
-
Coral Gables, Florida, Stany Zjednoczone, 33146
- UM Sylvester Comprehensive Cancer Center at Coral Gables
-
Deerfield Beach, Florida, Stany Zjednoczone, 33442
- UM Sylvester Comprehensive Cancer Center at Deerfield Beach
-
Fort Lauderdale, Florida, Stany Zjednoczone, 33316
- Broward Health Medical Center
-
Miami, Florida, Stany Zjednoczone, 33136
- University of Miami Miller School of Medicine-Sylvester Cancer Center
-
Miami, Florida, Stany Zjednoczone, 33176
- UM Sylvester Comprehensive Cancer Center at Kendall
-
Plantation, Florida, Stany Zjednoczone, 33324
- UM Sylvester Comprehensive Cancer Center at Plantation
-
-
Georgia
-
Atlanta, Georgia, Stany Zjednoczone, 30308
- Emory University Hospital Midtown
-
Atlanta, Georgia, Stany Zjednoczone, 30322
- Emory University Hospital/Winship Cancer Institute
-
-
Hawaii
-
Honolulu, Hawaii, Stany Zjednoczone, 96813
- Queen's Medical Center
-
Honolulu, Hawaii, Stany Zjednoczone, 96813
- Hawaii Cancer Care Inc - Waterfront Plaza
-
Honolulu, Hawaii, Stany Zjednoczone, 96813
- Queen's Cancer Cenrer - POB I
-
Honolulu, Hawaii, Stany Zjednoczone, 96817
- Queen's Cancer Center - Kuakini
-
‘Aiea, Hawaii, Stany Zjednoczone, 96701
- Hawaii Cancer Care - Westridge
-
-
Idaho
-
Boise, Idaho, Stany Zjednoczone, 83712
- Saint Luke's Cancer Institute - Boise
-
Coeur d'Alene, Idaho, Stany Zjednoczone, 83814
- Kootenai Health - Coeur d'Alene
-
Fruitland, Idaho, Stany Zjednoczone, 83619
- Saint Luke's Cancer Institute - Fruitland
-
Meridian, Idaho, Stany Zjednoczone, 83642
- Saint Luke's Cancer Institute - Meridian
-
Nampa, Idaho, Stany Zjednoczone, 83687
- Saint Luke's Cancer Institute - Nampa
-
Post Falls, Idaho, Stany Zjednoczone, 83854
- Kootenai Clinic Cancer Services - Post Falls
-
Sandpoint, Idaho, Stany Zjednoczone, 83864
- Kootenai Clinic Cancer Services - Sandpoint
-
Twin Falls, Idaho, Stany Zjednoczone, 83301
- Saint Luke's Cancer Institute - Twin Falls
-
-
Illinois
-
Aurora, Illinois, Stany Zjednoczone, 60504
- Rush-Copley Medical Center
-
Centralia, Illinois, Stany Zjednoczone, 62801
- Centralia Oncology Clinic
-
Chicago, Illinois, Stany Zjednoczone, 60637
- University of Chicago Comprehensive Cancer Center
-
Chicago, Illinois, Stany Zjednoczone, 60612
- University of Illinois
-
Chicago, Illinois, Stany Zjednoczone, 60612
- John H Stroger Jr Hospital of Cook County
-
Danville, Illinois, Stany Zjednoczone, 61832
- Carle at The Riverfront
-
Decatur, Illinois, Stany Zjednoczone, 62526
- Decatur Memorial Hospital
-
Decatur, Illinois, Stany Zjednoczone, 62526
- Cancer Care Specialists of Illinois - Decatur
-
Effingham, Illinois, Stany Zjednoczone, 62401
- Crossroads Cancer Center
-
Effingham, Illinois, Stany Zjednoczone, 62401
- Carle Physician Group-Effingham
-
Harvey, Illinois, Stany Zjednoczone, 60426
- Ingalls Memorial Hospital
-
Mattoon, Illinois, Stany Zjednoczone, 61938
- Carle Physician Group-Mattoon/Charleston
-
New Lenox, Illinois, Stany Zjednoczone, 60451
- UC Comprehensive Cancer Center at Silver Cross
-
O'Fallon, Illinois, Stany Zjednoczone, 62269
- Cancer Care Center of O'Fallon
-
O'Fallon, Illinois, Stany Zjednoczone, 62269
- HSHS Saint Elizabeth's Hospital
-
Orland Park, Illinois, Stany Zjednoczone, 60462
- University of Chicago Medicine-Orland Park
-
Springfield, Illinois, Stany Zjednoczone, 62702
- Southern Illinois University School of Medicine
-
Springfield, Illinois, Stany Zjednoczone, 62702
- Springfield Clinic
-
Springfield, Illinois, Stany Zjednoczone, 62781
- Springfield Memorial Hospital
-
Urbana, Illinois, Stany Zjednoczone, 61801
- Carle Cancer Center
-
Yorkville, Illinois, Stany Zjednoczone, 60560
- Rush-Copley Healthcare Center
-
-
Iowa
-
Ames, Iowa, Stany Zjednoczone, 50010
- Mary Greeley Medical Center
-
Ames, Iowa, Stany Zjednoczone, 50010
- McFarland Clinic - Ames
-
Ankeny, Iowa, Stany Zjednoczone, 50023
- UI Health Care Mission Cancer and Blood - Ankeny Clinic
-
Boone, Iowa, Stany Zjednoczone, 50036
- McFarland Clinic - Boone
-
Clive, Iowa, Stany Zjednoczone, 50325
- Mercy Cancer Center-West Lakes
-
Clive, Iowa, Stany Zjednoczone, 50325
- UI Health Care Mission Cancer and Blood - West Des Moines Clinic
-
Creston, Iowa, Stany Zjednoczone, 50801
- Greater Regional Medical Center
-
Des Moines, Iowa, Stany Zjednoczone, 50309
- Iowa Methodist Medical Center
-
Des Moines, Iowa, Stany Zjednoczone, 50314
- Mercy Medical Center - Des Moines
-
Des Moines, Iowa, Stany Zjednoczone, 50309
- UI Health Care Mission Cancer and Blood - Des Moines Clinic
-
Des Moines, Iowa, Stany Zjednoczone, 50314
- UI Health Care Mission Cancer and Blood - Laurel Clinic
-
Fort Dodge, Iowa, Stany Zjednoczone, 50501
- McFarland Clinic - Trinity Cancer Center
-
Jefferson, Iowa, Stany Zjednoczone, 50129
- McFarland Clinic - Jefferson
-
Marshalltown, Iowa, Stany Zjednoczone, 50158
- McFarland Clinic - Marshalltown
-
Waukee, Iowa, Stany Zjednoczone, 50263
- UI Health Care Mission Cancer and Blood - Waukee Clinic
-
West Des Moines, Iowa, Stany Zjednoczone, 50266
- Mercy Medical Center-West Lakes
-
-
Louisiana
-
New Orleans, Louisiana, Stany Zjednoczone, 70112
- University Medical Center New Orleans
-
-
Maryland
-
Baltimore, Maryland, Stany Zjednoczone, 21287
- Johns Hopkins University/Sidney Kimmel Cancer Center
-
Baltimore, Maryland, Stany Zjednoczone, 21204
- Greater Baltimore Medical Center
-
Baltimore, Maryland, Stany Zjednoczone, 21201
- University of Maryland/Greenebaum Cancer Center
-
Cumberland, Maryland, Stany Zjednoczone, 21502
- UPMC Western Maryland
-
-
Massachusetts
-
Worcester, Massachusetts, Stany Zjednoczone, 01655
- UMass Memorial Medical Center - University Campus
-
-
Minnesota
-
Coon Rapids, Minnesota, Stany Zjednoczone, 55433
- Mercy Hospital
-
Minneapolis, Minnesota, Stany Zjednoczone, 55415
- Hennepin County Medical Center
-
Minneapolis, Minnesota, Stany Zjednoczone, 55407
- Abbott-Northwestern Hospital
-
Saint Louis Park, Minnesota, Stany Zjednoczone, 55416
- Park Nicollet Clinic - Saint Louis Park
-
Saint Paul, Minnesota, Stany Zjednoczone, 55101
- Regions Hospital
-
-
Missouri
-
Cape Girardeau, Missouri, Stany Zjednoczone, 63703
- Saint Francis Medical Center
-
St Louis, Missouri, Stany Zjednoczone, 63128
- Mercy Hospital South
-
-
Montana
-
Anaconda, Montana, Stany Zjednoczone, 59711
- Community Hospital of Anaconda
-
Billings, Montana, Stany Zjednoczone, 59101
- Billings Clinic Cancer Center
-
Bozeman, Montana, Stany Zjednoczone, 59715
- Bozeman Health Deaconess Hospital
-
Great Falls, Montana, Stany Zjednoczone, 59405
- Benefis Sletten Cancer Institute
-
Missoula, Montana, Stany Zjednoczone, 59804
- Community Medical Center
-
-
New Hampshire
-
Lebanon, New Hampshire, Stany Zjednoczone, 03756
- Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center
-
-
New Mexico
-
Albuquerque, New Mexico, Stany Zjednoczone, 87106
- University of New Mexico Cancer Center
-
Las Cruces, New Mexico, Stany Zjednoczone, 88011
- Memorial Medical Center-Las Cruces
-
-
North Carolina
-
Clinton, North Carolina, Stany Zjednoczone, 28328
- Southeastern Medical Oncology Center-Clinton
-
Goldsboro, North Carolina, Stany Zjednoczone, 27534
- Southeastern Medical Oncology Center-Goldsboro
-
Jacksonville, North Carolina, Stany Zjednoczone, 28546
- Southeastern Medical Oncology Center-Jacksonville
-
-
Ohio
-
Centerville, Ohio, Stany Zjednoczone, 45459
- Miami Valley Hospital South
-
Dayton, Ohio, Stany Zjednoczone, 45409
- Miami Valley Hospital
-
Dayton, Ohio, Stany Zjednoczone, 45415
- Miami Valley Hospital North
-
Dayton, Ohio, Stany Zjednoczone, 45415
- Dayton Physician LLC - Englewood
-
Dayton, Ohio, Stany Zjednoczone, 45409
- Premier Blood and Cancer Center
-
Franklin, Ohio, Stany Zjednoczone, 45005-1066
- Atrium Medical Center-Middletown Regional Hospital
-
Greenville, Ohio, Stany Zjednoczone, 45331
- Miami Valley Cancer Care and Infusion
-
Kettering, Ohio, Stany Zjednoczone, 45429
- Kettering Medical Center
-
Steubenville, Ohio, Stany Zjednoczone, 43952
- Trinity's Tony Teramana Cancer Center
-
Toledo, Ohio, Stany Zjednoczone, 43623
- Toledo Clinic Cancer Centers-Toledo
-
Troy, Ohio, Stany Zjednoczone, 45373
- Upper Valley Medical Center
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Stany Zjednoczone, 73104
- University of Oklahoma Health Sciences Center
-
-
Oregon
-
Clackamas, Oregon, Stany Zjednoczone, 97015
- Providence Cancer Institute Clackamas Clinic
-
Newberg, Oregon, Stany Zjednoczone, 97132
- Providence Newberg Medical Center
-
Portland, Oregon, Stany Zjednoczone, 97213
- Providence Portland Medical Center
-
Portland, Oregon, Stany Zjednoczone, 97225
- Providence Saint Vincent Medical Center
-
-
Pennsylvania
-
Altoona, Pennsylvania, Stany Zjednoczone, 16601
- UPMC Altoona
-
Beaver, Pennsylvania, Stany Zjednoczone, 15009
- UPMC-Heritage Valley Health System Beaver
-
Butler, Pennsylvania, Stany Zjednoczone, 16001
- UPMC Hillman Cancer Center at Butler Health System
-
Camp Hill, Pennsylvania, Stany Zjednoczone, 17011
- UPMC Camp Hill
-
Carlisle, Pennsylvania, Stany Zjednoczone, 17015
- Carlisle Regional Cancer Center
-
Cranberry Township, Pennsylvania, Stany Zjednoczone, 16066
- UPMC Hillman Cancer Center - Passavant - Cranberry
-
Erie, Pennsylvania, Stany Zjednoczone, 16505
- UPMC Hillman Cancer Center Erie
-
Farrell, Pennsylvania, Stany Zjednoczone, 16121
- UPMC Cancer Center at UPMC Horizon
-
Greensburg, Pennsylvania, Stany Zjednoczone, 15601
- UPMC Cancer Centers - Arnold Palmer Pavilion
-
Greenville, Pennsylvania, Stany Zjednoczone, 16125
- UPMC Hillman Cancer Center in Greenville/UPMC Horizon
-
Harrisburg, Pennsylvania, Stany Zjednoczone, 17109
- UPMC Pinnacle Cancer Center/Community Osteopathic Campus
-
Indiana, Pennsylvania, Stany Zjednoczone, 15701
- IRMC Cancer Center
-
Johnstown, Pennsylvania, Stany Zjednoczone, 15901
- UPMC-Johnstown/John P. Murtha Regional Cancer Center
-
McKeesport, Pennsylvania, Stany Zjednoczone, 15132
- UPMC Cancer Center at UPMC McKeesport
-
Mechanicsburg, Pennsylvania, Stany Zjednoczone, 17050
- UPMC Hillman Cancer Center at Rocco And Nancy Ortenzio Cancer Pavilion
-
Monroeville, Pennsylvania, Stany Zjednoczone, 15146
- Forbes Hospital
-
Monroeville, Pennsylvania, Stany Zjednoczone, 15146
- UPMC Hillman Cancer Center - Monroeville
-
Moon Township, Pennsylvania, Stany Zjednoczone, 15108
- UPMC Hillman Cancer Center in Coraopolis
-
Mount Pleasant, Pennsylvania, Stany Zjednoczone, 15666
- UPMC Hillman Cancer Center - Part of Frick Hospital
-
N. Huntingdon, Pennsylvania, Stany Zjednoczone, 15642
- Arnold Palmer Cancer Center Medical Oncology Norwin
-
Natrona Heights, Pennsylvania, Stany Zjednoczone, 15065
- UPMC Cancer Center-Natrona Heights
-
New Castle, Pennsylvania, Stany Zjednoczone, 16105
- UPMC Hillman Cancer Center - New Castle
-
Philadelphia, Pennsylvania, Stany Zjednoczone, 19107
- Thomas Jefferson University Hospital
-
Philadelphia, Pennsylvania, Stany Zjednoczone, 19114
- Jefferson Torresdale Hospital
-
Pittsburgh, Pennsylvania, Stany Zjednoczone, 15212
- Allegheny General Hospital
-
Pittsburgh, Pennsylvania, Stany Zjednoczone, 15232
- UPMC Hillman Cancer Center
-
Pittsburgh, Pennsylvania, Stany Zjednoczone, 15215
- UPMC-Saint Margaret
-
Pittsburgh, Pennsylvania, Stany Zjednoczone, 15237
- UPMC-Passavant Hospital
-
Pittsburgh, Pennsylvania, Stany Zjednoczone, 15243
- UPMC-Saint Clair Hospital Cancer Center
-
Pittsburgh, Pennsylvania, Stany Zjednoczone, 15219
- UPMC-Mercy Hospital
-
Seneca, Pennsylvania, Stany Zjednoczone, 16346
- UPMC Cancer Center at UPMC Northwest
-
Uniontown, Pennsylvania, Stany Zjednoczone, 15401
- UPMC Cancer Center-Uniontown
-
Washington, Pennsylvania, Stany Zjednoczone, 15301
- UPMC Cancer Center-Washington
-
West Mifflin, Pennsylvania, Stany Zjednoczone, 15122
- UPMC West Mifflin-Cancer Center Jefferson
-
Williamsport, Pennsylvania, Stany Zjednoczone, 17754
- Divine Providence Hospital
-
Willow Grove, Pennsylvania, Stany Zjednoczone, 19090
- Asplundh Cancer Pavilion
-
York, Pennsylvania, Stany Zjednoczone, 17408
- UPMC Memorial
-
-
Rhode Island
-
Westerly, Rhode Island, Stany Zjednoczone, 02891
- Smilow Cancer Hospital Care Center - Westerly
-
-
South Dakota
-
Rapid City, South Dakota, Stany Zjednoczone, 57701
- Rapid City Regional Hospital
-
-
Tennessee
-
Knoxville, Tennessee, Stany Zjednoczone, 37916
- Covenant Health Cancer Centers
-
Knoxville, Tennessee, Stany Zjednoczone, 37932
- Covenant Health Cancer Centers - West
-
Lenoir City, Tennessee, Stany Zjednoczone, 37772
- Covenant Health Oncology Group - Lenoir City
-
Nashville, Tennessee, Stany Zjednoczone, 37232
- Vanderbilt University/Ingram Cancer Center
-
Oak Ridge, Tennessee, Stany Zjednoczone, 37830
- Covenant Health Oncology Group - Oak Ridge
-
-
Vermont
-
Saint Johnsbury, Vermont, Stany Zjednoczone, 05819
- Dartmouth Cancer Center - North
-
-
West Virginia
-
Charleston, West Virginia, Stany Zjednoczone, 25304
- Vandalia Health/CAMC Institute for Academic Medicine
-
-
Wisconsin
-
Mukwonago, Wisconsin, Stany Zjednoczone, 53149
- ProHealth D N Greenwald Center
-
Oconomowoc, Wisconsin, Stany Zjednoczone, 53066
- ProHealth Oconomowoc Memorial Hospital
-
Waukesha, Wisconsin, Stany Zjednoczone, 53188
- UW Cancer Center at ProHealth Care
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Opis
Inclusion Criteria:
-
Patient must have histologically confirmed squamous cell carcinoma of the head and neck (HNSCC) (excluding squamous cell carcinoma [SCC] of salivary glands, Epstein-Barr virus [EBV]-associated nasopharynx and skin)
-
Patient must have measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1. Measurements must be obtained within 4 weeks prior to randomization
-
Patient must be >= 18 years of age
-
Patient must have an Eastern Cooperative Oncology Group (ECOG) performance status 0-1
-
Patient must have disease progression after prior therapy with an immune checkpoint inhibitor (ICI) in the first-line setting for recurrent/metastatic disease. Patient must have received first-line immune checkpoint inhibition for at least 6 weeks. Patients who have recurred or progressed within 12 weeks of immune checkpoint inhibition administered in the definitive setting for locally advanced disease (for e.g., in the context of a clinical trial) will also be eligible if local therapies are not feasible
-
Prior combination immunotherapies are permitted, but patient must not have had prior antiangiogenic treatment (e.g., bevacizumab, ziv-aflibercept, ramucirumab, sorafenib, sunitinib, pazopanib, regorafenib, lenvatinib, etc.). Patient must have completed any prior investigational therapy at least 28 days prior to randomization.
- NOTE: Patients who received platinum/taxanes in the locally-advanced or recurrent/metastatic setting and did not progress for at least 4 months thereafter, will be eligible for this study. Patients who received cetuximab in the locally-advanced setting and did not progress for at least 4 months thereafter, will also be eligible for this study
-
Patient must not have a history of >= grade 3 immune-related adverse event on prior ICI therapy (except those that could be managed with steroids [e.g., dermatologic toxicity, asymptomatic elevation of pancreatic enzymes, etc.]) and ICI could eventually be resumed. Patients who developed grade 3 endocrinopathies but are now stable on hormone supplementation and/or a daily prednisone dose of =< 10 mg (or equivalent doses of another glucocorticoid), will be permitted on this trial
-
Patient must not have a history of PD-1 inhibitor-induced hyper-progression, defined as 100% increase in tumor burden within 8 weeks (or 50% within 4 weeks) of initiating ICI and associated with clinical deterioration
-
Patient must not have any of the following criteria due to the possibility of increased risk for tumor bleeding with bevacizumab therapy:
- Prior carotid bleeding,
- Tumors that invade major vessels (e.g., the carotid) as shown unequivocally by imaging studies,
- Central (e.g., within 2 cm from the hilum) lung metastases that are cavitary as shown unequivocally by imaging studies,
- Any prior history of bleeding related to the current head and neck cancer,
- History of gross hemoptysis (bright red blood of 1/2 teaspoon or more per episode of coughing) within 3 months prior to randomization
-
Patient must not have uncontrolled hypertension, a history of hypertensive crisis or hypertensive encephalopathy, or a history of grade 4 thromboembolism
-
Patient must not have a history of coagulopathy or hemorrhagic disorders
-
Patient must not have a history of thrombosis (e.g., pulmonary embolism or deep venous thrombosis) currently requiring therapeutic anticoagulation (prophylactic use of anticoagulation is allowed)
-
Patient must not be receiving chronic daily treatment with aspirin (> 325 mg/day) or non-steroidal anti-inflammatory agents (NSAID's) known to inhibit platelet function. The use of anti-platelet agents [e.g., dipyridamole (Persatine), ticlopidine (Ticlid), clopidogrel (Plavix)] is allowed only if patient is not receiving concurrent aspirin or NSAID's known to inhibit platelet function
-
Patient must have PD-L1 expression >= 1% by CPS in the tumor and/or immune cells
- NOTE: Enrolling centers should test for PD-L1 CPS preferably using the SP263 assay. Where this is not feasible, using their preferred Clinical Laboratory Improvement Act (CLIA)-certified or similar assay will be accepted. It is preferred for standard of care (SOC) PD-L1 assessments to be done on post-first line ICI samples if available, but SOC PD-L1 assessments on pre-ICI samples will be accepted for eligibility
-
Patient must not have a severe infection within 4 weeks prior to randomization, including, but not limited to, hospitalization for complications of infection, bacteremia, or severe pneumonia. Patients must not have active tuberculosis
-
Patient must not have a history of non-infectious pneumonitis requiring steroids at doses greater than or equal to 10 mg per day of prednisone or the equivalent on first line immunotherapy
-
Patient must not have a history of solid organ transplantation or stem-cell transplant
-
Patient must not be on immunosuppressive medication within 7 days prior to randomization except for: intranasal, inhaled, or topical steroids, local steroid injection, systemic corticosteroids at doses less than or equal to 10 mg per day of prednisone or the equivalent, or steroids used as premedication for hypersensitivity reactions
-
Patient must not have an active autoimmune disease that requires systemic treatment within 2 years prior to randomization. Patients who are receiving replacement therapy for adrenal or pituitary insufficiency will not be excluded
-
Patient must not have had a severe hypersensitivity reaction to any of the drug components used on this protocol or to chimeric or humanized antibodies or fusion proteins
-
Patient must not have received any live vaccine within 30 days prior to randomization and while participating in the study (and continue for 5 months after the last dose of atezolizumab on Arm C). Live vaccines include, but are not limited to, the following: measles, mumps, rubella, chicken pox, yellow fever, rabies, bacillus Calmette-Guerin (BCG), and typhoid (oral) vaccine. Patients are permitted to receive inactivated vaccines and any non-live vaccines including those for the seasonal influenza and coronavirus disease 2019 (COVID-19) (Note: intranasal influenza vaccines, such as Flu-Mist [registered trademark] are live attenuated vaccines and are not allowed). If possible, it is recommended to separate study drug administration from vaccine administration by about a week (primarily, in order to minimize an overlap of adverse events
-
Patient must not be pregnant or breast-feeding due to the potential harm to an unborn fetus and possible risk for adverse events in nursing infants with the treatment regimens being used.
- All patients of childbearing potential must have a blood test or urine study within 14 days prior to randomization to rule out pregnancy.
- A patient of childbearing potential is defined as anyone, regardless of sexual orientation or whether they have undergone tubal ligation, who meets the following criteria: 1) has achieved menarche at some point, 2) has not undergone a hysterectomy or bilateral oophorectomy; or 3) has not been naturally postmenopausal (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months)
-
Patients must not expect to conceive or father children by using accepted and effective method(s) of contraception or by abstaining from sexual intercourse for the duration of their participation in the study and for 2 months after the last dose of treatment for patients assigned to Arm A and for 6 months after the last dose of protocol treatment for patients assigned to Arms B or C.
- NOTE: Patients must also not breastfeed while on treatment and for 2 months after the last dose of treatment for patients assigned to Arm A and for 6 months after the last dose of treatment for patients assigned to Arms B or C
-
Patient must have the ability to understand and the willingness to sign a written informed consent document. Patients with impaired decision-making capacity (IDMC) who have a legally authorized representative (LAR) or caregiver and/or family member available will also be considered eligible
-
Leukocytes >= 3,000/mcL (must be obtained =< 14 days prior to protocol randomization)
-
Absolute neutrophil count (ANC) >= 1,500/mcL (must be obtained =< 14 days prior to protocol randomization)
-
Platelets >= 100,000/mcL (must be obtained =< 14 days prior to protocol randomization)
-
Hemoglobin (Hgb) > 9 g/dL (must be obtained =< 14 days prior to protocol randomization) (Note: Patient may be transfused to meet this criteria)
-
Total bilirubin =< 2.0 x institutional upper limit of normal (ULN) (=< 5.0 x institutional ULN if hepatic metastases present or =< 3 x ULN for patients with known Gilbert's disease) (must be obtained =< 14 days prior to protocol randomization)
-
Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT]) and alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 2.5 x institutional ULN (< 5.0 x institutional ULN if hepatic metastases present) (must be obtained =< 14 days prior to protocol randomization)
-
Alkaline phosphatase < 2.5 x institutional ULN (< 5.0 x institutional ULN if hepatic or bone metastases present) (must be obtained =< 14 days prior to protocol randomization)
-
Creatinine =< 1.5 x institutional ULN (must be obtained =< 14 days prior to protocol randomization)
-
Patients with uncontrolled or symptomatic hypercalcemia (ionized calcium > 1.5 mmol/L, calcium > 12 mg/dL or corrected serum calcium > ULN) must have their calcium levels corrected prior to randomization
-
Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months of randomization are eligible for this trial
-
For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated
-
Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load
-
Patients with treated brain metastases are eligible if follow-up brain imaging after central nervous system (CNS)-directed therapy shows no evidence of progression. Patients must not have untreated brain metastases or leptomeningeal disease
-
Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial
-
Patients must not have uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures (once monthly or more frequently). Patients may have indwelling catheters (e.g., PleurX [registered trademark])
-
Patient must not have significant cardiovascular disease (such as New York Heart Association class II or greater cardiac disease, myocardial infarction, or cerebrovascular accident) within 3 months prior to randomization, or unstable arrhythmia or unstable angina at the time of randomization
-
Patient must not receive any other chemotherapy, immunotherapy, antitumor hormonal therapy (excluding contraceptives and replacement steroids), radiation therapy, or experimental medications while on protocol treatment. Symptomatic lesions (e.g., bone metastases or metastases causing nerve impingement) amenable to palliative radiotherapy should be treated prior to randomization and patients must be recovered from the effects of radiation (there is no required minimum recovery period
-
Patient must not have had a surgical procedure (including open biopsy, surgical resection, wound revision, or any other major surgery involving entry into a body cavity) or significant traumatic injury within 28 days prior to randomization, or anticipation of need for major surgical procedure while on protocol treatment
-
Patient must not have any other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding that contraindicates the use of the agents used in this protocol, may affect the interpretation of the results, or may render the patient at high risk from treatment complications
-
Patient must not have a history of abdominal fistula, gastrointestinal (GI) perforation, intra-abdominal abscess, or active GI bleeding within 6 months prior to randomization
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Leczenie
- Przydział: Randomizowane
- Model interwencyjny: Zadanie sekwencyjne
- Maskowanie: Brak (otwarta etykieta)
Broń i interwencje
Grupa uczestników / Arm |
Interwencja / Leczenie |
|---|---|
|
Aktywny komparator: Phase II, Arm A (Cetuximab, Docetaxel, Cisplatin, Carboplatin)
Patients receive cetuximab IV over 60-120 minutes on days 1, 8, and 15 of each cycle, docetaxel IV over 1 hour on day 1 or days 1 and 8 of each cycle, and cisplatin IV or carboplatin IV on day 1 or days 1 and 8 of each cycle. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive cetuximab IV over 60-120 minutes on days 1, 8, and 15 or days 1 and 15 of each cycle of maintenance therapy. Cycles repeat every 21 days for 2 years in the absence of disease progression or unacceptable toxicity. Patients undergo a CT scan, a PET scan, and/or MRI throughout the trial. Patients may undergo ECHO during screening. Patients undergo blood sample collection throughout the study. |
Given IV
Inne nazwy:
Given IV
Inne nazwy:
Given IV
Inne nazwy:
Undergo blood sample collection
Inne nazwy:
Undergo MRI
Inne nazwy:
Undergo ECHO
Inne nazwy:
Undergo CT scan
Inne nazwy:
Undergo PET scan
Inne nazwy:
Given IV
Inne nazwy:
|
|
Eksperymentalny: Phase II, Arm B(Docetaxel, Cisplatin/Carboplatin, Bevacizumab)
Patients receive bevacizumab IV over 30-90 minutes on day 1 of each cycle, docetaxel IV over 1 hour on day 1 or days 1 and 8 of each cycle, and cisplatin IV or carboplatin IV on day 1 or days 1 and 8 of each cycle. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive bevacizumab IV over 30-60 minutes on day 1 of each cycle of maintenance therapy. Cycles repeat every 21 days for 2 years in the absence of disease progression or unacceptable toxicity. Patients undergo a CT scan, a PET scan, and/or MRI throughout the trial. Patients may undergo ECHO during screening. Patients undergo blood sample collection throughout the study. |
Given IV
Inne nazwy:
Given IV
Inne nazwy:
Given IV
Inne nazwy:
Given IV
Inne nazwy:
Undergo blood sample collection
Inne nazwy:
Undergo MRI
Inne nazwy:
Undergo ECHO
Inne nazwy:
Undergo CT scan
Inne nazwy:
Undergo PET scan
Inne nazwy:
|
|
Eksperymentalny: Phase II, Arm C (Bevacizumab, Atezolizumab)
Patients receive bevacizumab IV over 30-90 minutes on day 1 and atezolizumab IV over 30-60 minutes on day 1 of each cycle. Cycles repeat every 21 days for 2 years in the absence of disease progression or unacceptable toxicity. Patients undergo a CT scan, a PET scan, and/or MRI throughout the trial. Patients may undergo ECHO during screening. Patients undergo blood sample collection throughout the study. |
Given IV
Inne nazwy:
Undergo blood sample collection
Inne nazwy:
Undergo MRI
Inne nazwy:
Undergo ECHO
Inne nazwy:
Undergo CT scan
Inne nazwy:
Undergo PET scan
Inne nazwy:
Given IV
Inne nazwy:
|
|
Eksperymentalny: Phase III, Arm A (Cetuximab, Docetaxel, Cisplatin/Carboplatin)
Patients receive cetuximab IV over 60-120 minutes on days 1, 8, and 15 of each cycle, docetaxel IV over 1 hour on day 1 or days 1 and 8 of each cycle, and cisplatin IV or carboplatin IV on day 1 or days 1 and 8 of each cycle. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive cetuximab IV over 60-120 minutes on days 1, 8, and 15 or days 1 and 15 of each cycle of maintenance therapy. Cycles repeat every 21 days for 2 years in the absence of disease progression or unacceptable toxicity. Patients undergo a CT scan, a PET scan, and/or MRI throughout the trial. Patients may undergo ECHO during screening. Patients undergo blood sample collection throughout the study. |
Given IV
Inne nazwy:
Given IV
Inne nazwy:
Given IV
Inne nazwy:
Undergo blood sample collection
Inne nazwy:
Undergo MRI
Inne nazwy:
Undergo ECHO
Inne nazwy:
Undergo CT scan
Inne nazwy:
Undergo PET scan
Inne nazwy:
Given IV
Inne nazwy:
|
|
Eksperymentalny: Phase III, Arm B (Chemotherapy, Bevacizumab, Atezolizumab)
Patients receive treatment as in Arm B or C above based on results of the Phase II trial. |
Given IV
Inne nazwy:
Given IV
Inne nazwy:
Given IV
Inne nazwy:
Given IV
Inne nazwy:
Undergo MRI
Inne nazwy:
Undergo ECHO
Inne nazwy:
Undergo CT scan
Inne nazwy:
Undergo PET scan
Inne nazwy:
Given IV
Inne nazwy:
|
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Czas przeżycia bez progresji choroby (PFS) (faza II)
Ramy czasowe: Czas od rozpoczęcia leczenia do progresji choroby lub zgonu, oceniany do 5 lat od randomizacji
|
Czas od rozpoczęcia leczenia do progresji choroby lub zgonu, oceniany do 5 lat od randomizacji
|
|
|
Overall survival (OS) (Phase III)
Ramy czasowe: Time from treatment initiation until death from any cause, assessed up to 5 years from randomization
|
Will be compared using a stratified log rank test. |
Time from treatment initiation until death from any cause, assessed up to 5 years from randomization
|
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Częstość występowania zdarzeń niepożądanych (faza III)
Ramy czasowe: Do 30 dni po zakończeniu kuracji
|
Do 30 dni po zakończeniu kuracji
|
|
|
OS in the subset of patients with high PD-L1 expression (Phase III)
Ramy czasowe: Up to 5 years from randomization
|
The interaction of PD-L1 by treatment will also be evaluated in a Cox proportional hazards model. |
Up to 5 years from randomization
|
|
Correlation between fludeoxyglucose F-18 (18F-FDG) positron emission tomography (PET) and computed tomography (CT) neck imaging biomarkers
Ramy czasowe: Up to 5 years from randomization
|
The two-sample t-test will be used to compare the difference of baseline 18F -FDG PET /CT imaging biomarkers (maximum standardized uptake value [SUVmax], metabolic tumor volume [MTV], total lesion glycolysis [TLG], tumor volume) between low and high expression of PD-L1. |
Up to 5 years from randomization
|
|
Prediction of treatment response
Ramy czasowe: Baseline up to 12 weeks
|
Determined by 18FDG-PET/CT and CT neck imaging biomarkers. To determine if 18FDG-PET/CT and CT neck imaging biomarkers at baseline will predict treatment response at nine to twelve weeks post-treatment, PFS, and OS Logistic regression model will be fit to assess the association of the 18F -FDG PET /CT imaging biomarkers (e.g., SUVmax, MTV, TLG, tumor heterogeneity, tumor volume) with binary treatment response at 9-12 weeks post treatment. Cox proportional hazards models will be fit to assess the association of 18F -FDG PET /CT imaging biomarkers with time-to-event outcomes (PFS or OS). |
Baseline up to 12 weeks
|
Inne miary wyników
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Correlation between 18F-FDG PET and CT neck radiomics features and expression of PD-L1 expression
Ramy czasowe: Up to 5 years from randomization
|
The imaging textural features from radiomics analysis will be associated with the dichotomized PD-L1 expressions. First, proper transformation will be applied to the textural features as needed to address the distribution skewness. Second, Pearson or Spearman rank correlations will be calculated between all pairs of textural features to identify highly correlated features. Third, to address overfitting and high collinearity, machine learning techniques (e.g., LASSO or XGBoost) will be employed for feature selection during the association analysis with PD-L1 expressions. |
Up to 5 years from randomization
|
Współpracownicy i badacze
Sponsor
Śledczy
- Główny śledczy: Aarti Bhatia, ECOG-ACRIN Cancer Research Group
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Rzeczywisty)
Zakończenie podstawowe (Szacowany)
Ukończenie studiów (Szacowany)
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Rzeczywisty)
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Dodatkowe istotne warunki MeSH
- Choroby jamy ustnej
- Choroby Stomatognatyczne
- Nowotwory według lokalizacji
- Nowotwory
- Choroby Układu Oddechowego
- Nowotwory według typu histologicznego
- Nowotwory głowy i szyi
- Nowotwory gruczołowe i nabłonkowe
- Nowotwory Układu Oddechowego
- Choroby otorynolaryngologiczne
- Nowotwory gardła
- Nowotwory otorynolaryngologiczne
- Choroby jamy nosowo-gardłowej
- Choroby gardła
- Rak, płaskonabłonkowy
- Choroby krtani
- Nowotwory jamy nosowo-gardłowej
- Rak jamy nosowo-gardłowej
- Rak płaskonabłonkowy głowy i szyi
- Rak
- Nowotwory krtani
- Nowotwory jamy ustnej
- Nowotwory jamy ustnej i gardła
- Nowotwory gardła dolnego
- Limfoidalne zapalenie płuc
- Aminokwasy, peptydy i białka
- Białka
- Związki siarki
- Organiczne chemikalia
- Techniki śledcze
- Techniki laboratoryjne kliniczne
- Techniki i procedury diagnostyczne
- Diagnoza
- Węglowodory
- Cykloparafiny
- Węglowodory, Alicyklic
- Węglowodory, cykliczne
- Terpeny
- Przeciwciała, monoklonalne, humanizowane
- Przeciwciała, monoklonalne
- Przeciwciała
- Immunoglobuliny
- Immunoproteiny
- Białka krwi
- Globuliny w surowicy
- Globuliny
- Chemikalia nieorganiczne
- Związki chloru
- Związki azotu
- Kompleksy koordynacyjne
- Taksoidy
- Cyklodekan
- Diterpenes
- Elementy
- Metale
- Techniki chemii, analityczne
- Analiza widma
- Metale, ciężkie
- Izotypy immunoglobuliny
- Siarczki
- Aniony
- Jony
- Elektrolity
- Siarkowodór
- Związki platynowe
- Elementy przejściowe
- Docetaksel
- Bewacyzumab
- Cetuksymab
- Karboplatyna
- Immunoglobulina G
- Cisplatyna
- Cytrynian 1,2-diaminocykloheksanoplatyny II
- Prowadzenie okazów
- Spektroskopia rezonansu magnetycznego
- Disiarczki
- Platyna
- Atezolizumab
- (225) AC-Dota-C (RGDYK)
Inne numery identyfikacyjne badania
- NCI-2021-10021
- U10CA180820 (Grant/umowa NIH USA)
- NCI-2021-10021 (Identyfikator rejestru: CTRP (Clinical Trial Reporting Program))
- EA3202 (Inny identyfikator: CTEP)
- EA3202 (Inny identyfikator: ECOG-ACRIN Cancer Research Group)
Plan dla danych uczestnika indywidualnego (IPD)
Planujesz udostępniać dane poszczególnych uczestników (IPD)?
Opis planu IPD
NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Bada produkt urządzenia regulowany przez amerykańską FDA
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .